Table 1.
Baseline demographic and clinical characteristics (n = 60)
| Characteristic | Values |
|---|---|
| Age, mean ± SD, years | 59.3 ± 9.1 |
| Sex, n (%) | |
| Female | 25 (41.7) |
| Male | 35 (58.3) |
| Psoriasis duration, mean ± SD, years | 13.3 ± 11.6 |
| Psoriatic arthritis, n (%) | 17 (28.3) |
| Duration, mean ± SD, years | 7.8 ± 7.1 |
| Comorbidities, n (%) | |
| Hypertension | 41 (68.3) |
| Dyslipidemia | 27 (45.0) |
| Diabetes mellitus | 21 (35.0) |
| Cardiopathy | 17 (28.3) |
| Othersa | 12 (20.0) |
| Prior systemic treatment for psoriasis, n (%) | |
| Cyclosporine | 31 (51.7) |
| Methotrexate | 21 (35.0) |
| Phototherapy | 17 (28.3) |
| Adalimumab | 14 (23.3) |
| Ustekinumab | 11 (18.3) |
| Acitretin | 9 (15.0) |
| Etanercept | 6 (10.0) |
| Infliximab | 3 (5.0) |
| Golimumab | 2 (3.3) |
| Transaminase values, IU/mL, mean ± SD | |
| Aspartate aminotransferase | 31.4 ± 15.8 |
| Alanine aminotransferase | 27.9 ± 18.6 |
| HBV/HCV-associated features, n (%) | |
| HBsAg positive | 13 (21.7) |
| HBcAb positive | 19 (31.7) |
| HBsAb positive | 16 (26.7) |
| HBeAg positive | 1 (16.7) |
| HBeAb positive | 4 (6.7) |
| Anti-HCV antibody positive | 30 (50.0) |
| HCV-RNA positive | 0 (0.0) |
HBcAb HBV core antibody, HBeAb hepatitis B e-antibody, HBeAg hepatitis B e-antigen, HBsAb HBV surface antibody, HBsAg hepatitis B surface antigen, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, SD standard deviation
aAutoimmune disease (n = 5), anxiety (n = 3), and chronic obstructive pulmonary disease, renal failure, fibromyalgia, and HIV infection in one patient each